BiondVax Pharmaceuticals Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Amir Reichman
- Full Time Employees
- 33
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Jerusalem BioPark Building Jerusalem Israel
- IPO Date
- May 12, 2015
- CIK
- 0001611747
- Website
- biondvax.com
- Similar Companies
- Business
- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), founded in 2003 and headquartered in Jerusalem, Israel, rebranded as Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) in September 2023 to reflect its strategic pivot from universal influenza vaccine development to innovative inflammation and immunology therapeutics alongside boutique contract development and manufacturing organization services; the company develops, manufactures, and commercializes Alpaca-derived nanosized antibodies (NanoAbs or VHH-antibodies) targeting autoimmune diseases such as psoriasis and asthma, infectious conditions including COVID-19, and other indications with unmet needs, while its Scinai Bioservices unit provides end-to-end biologics support from molecule selection and process development through cGMP manufacturing for preclinical, clinical, and Phase 3 trials, backed by over 20 years of experience and FDA/EMA-compliant facilities. Scinai operates primarily in Israel with global partnerships, including ongoing collaborations with the Max Planck Institute for Multidisciplinary Sciences and University Medical Center Göttingen for NanoAb discovery and optimization, serving biotech innovators and targeting large markets through systemic administration formats with enhanced half-life and patient compliance. Recent developments include reporting nine-month 2025 financial results on December 2, 2025, highlighting CDMO revenue growth and pipeline advances such as dual-target VHH-Fc NanoAbs for multiple I&I indications, four new NanoAbs with patent filings and exclusive licensing options by Q1 2026, securing a $10 million Standby Equity Purchase Agreement in March 2025 for flexible capital access to fund R&D and operations, raising $1.38 million via drawdowns in June 2025 ahead of BIO International Convention, and obtaining an option to acquire Pincell in March 2025 for its preclinical mAb PC-111 targeting rare dermatologic diseases like pemphigus vulgaris with EMA orphan designation.
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd.
BiondVax Reports Second Quarter Financial Results and Provides Business Update
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
BiondVax to Present at BIO-Europe Spring
BiondVax Presenting at BIO CEO & Investor Conference
Best Penny Stocks To Buy? 5 To Watch After Big News This Week
BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco
BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference
BiondVax to Present at LD Micro Investor Conference in Los Angeles
BiondVax to present at LD Micro Investor Conference in Los Angeles
BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference
BiondVax to Present at this week's Biomed Israel Conference
BiondVax Pharmaceuticals Ltd. (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call Transcript
BiondVax Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Why Is BiondVax (BVXV) Stock Up Today?
Here's Why Biondvax Pharmaceuticals Shares Are Rising
Trading Penny Stocks? Top Stock Market News for March 24th, 2022
BiondVax to Present at Aegis Virtual Conference
BiondVax to Present at BIO CEO & Investor Conference
BiondVax to Present at Edison Group's Open House Conference